Hematological
malignancy- a term specified to a set of cancers that hit and affects the bone
marrow, lymph nodes and blood. Generally, the patients who suffer from
Lymphomas, Myelomas and Leukemia are not able to discover a permanent treatment
for their illness and do not survive the condition.
However,
the latest advancements prove that gene therapy can be an exceptional
development for the cure of various types of blood cancers. Researchers are
positive about the usage of gene therapy in which the blood cells can actually
be used to attack the cancerous cells. The testing’s, up till now have given
promising outcomes and the patients does not show any signs and symptoms of
cancer, after this medical treatment. This is genuinely accurate even for the
myeloma, chronic lymphocytic leukemia and lymphocytic leukemia patients who
were taking regular chemotherapies for years:
“Cancer was so advanced in
8-year-old Emily Whitehead of Philipsburg, Pa., that doctors said her major
organs would fail within days. She was the first child given the gene therapy
and shows no sign of cancer today, nearly two years later.”
In
this treatment, the doctors are actually sorting out the white blood cells from
the blood in massive quantities. These cells are then introduced in a lab to a
particular gene targeting cancer, and then are induced back in the patient’s
blood over a period of three days. This way, cancer is treated successfully and
in a more productive method than chemotherapies, bone marrow transplants or
stem cell.
Current
Gene Therapy is a conventional, bi-monthly peer-reviewed journal from the
shelves of Bentham Science Publishers. It has an impact factor rating, (5.318)
and is indexed in major abstracting agencies, that includes; Scopus,
EMBASE, MEDLINE/Index Medicus, and Journal Citation Reports etc. Current
Gene Therapy publishes major topics concerning basic and clinical applications
of gene and cell therapy. http://benthamscience.com/cgt/
No comments:
Post a Comment